Diagnoptics. Non-invasive assesment of cardiovascular risk and risk of diabetes.

Advanced Glycation Endproducts

Advanced Glycation Endproducts play a key role in the development of chronic age-related diseases such as diabetes, renal failure and cardiovascular disease.

Cardiovascular risk

Advanced Glycation Endproducts play a key role in the development of chronic age-related diseases such as diabetes, renal failure and cardiovascular disease.

About Diagnoptics

"Our results show that skin autofluorescence is strongly correlated with the presence and severity of erectile dysfunction (ED) in men with diabetes. AGEs contribute to the pathogenesis of the vascular complications of diabetes, and so measuring levels of these compounds may improve our ability to estimate the risk of complications in diabetic patients with ED." Kouidrat et al (2017); Journal of Diabetes and its complications

The AGE Reader App!

The new AGE Reader App allows you to generate a comprehensive Cardiovascular Risk Report based on the AGE Reader measurement. For each patient all visits can be documented and consulted in the easy to use App.

Read more »

More information

Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader to be presented at the DDG Diabetes Congress in Berlin 2018

Groningen, the Netherlands – April 11, 2018.

The AGE Reader will be showcased this year at the DDG Diabetes Congress by our German Distributor, » Read more

The AGE Reader and Diab-spot have received approval in a number of countries. Please check with the distributor in your country or Diagnoptics what the regulatory approval status is in your country. US Caution: Federal law restricts the AGE Reader and Diab-spot system to investigational use only. Commercial distribution has not been granted by the US FDA. Please see the AGE Reader and Diab-spot user manuals for descriptions of all relevant warnings, cautions, contraindications and safety information.